IL164275A0 - Pharmaceutical compositions containing carbon-2-modified-viatimin d analogs - Google Patents

Pharmaceutical compositions containing carbon-2-modified-viatimin d analogs

Info

Publication number
IL164275A0
IL164275A0 IL16427503A IL16427503A IL164275A0 IL 164275 A0 IL164275 A0 IL 164275A0 IL 16427503 A IL16427503 A IL 16427503A IL 16427503 A IL16427503 A IL 16427503A IL 164275 A0 IL164275 A0 IL 164275A0
Authority
IL
Israel
Prior art keywords
bone
modified
analogs
growth
stimulate
Prior art date
Application number
IL16427503A
Other languages
English (en)
Original Assignee
Wisonsin Alumni Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28673538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL164275(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisonsin Alumni Res Foundation filed Critical Wisonsin Alumni Res Foundation
Publication of IL164275A0 publication Critical patent/IL164275A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
IL16427503A 2002-03-25 2003-03-12 Pharmaceutical compositions containing carbon-2-modified-viatimin d analogs IL164275A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/105,826 US20030195175A1 (en) 2002-03-25 2002-03-25 Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
PCT/US2003/007443 WO2003082300A1 (en) 2002-03-25 2003-03-12 Use of carbon-2-modified-vitamin d analogs to induce the formation of new bone

Publications (1)

Publication Number Publication Date
IL164275A0 true IL164275A0 (en) 2005-12-18

Family

ID=28673538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16427503A IL164275A0 (en) 2002-03-25 2003-03-12 Pharmaceutical compositions containing carbon-2-modified-viatimin d analogs

Country Status (20)

Country Link
US (3) US20030195175A1 (da)
EP (1) EP1494680B1 (da)
JP (1) JP2005527558A (da)
KR (1) KR100983953B1 (da)
CN (1) CN100531739C (da)
AT (1) ATE406901T1 (da)
AU (1) AU2003220169B2 (da)
BR (1) BR0308701A (da)
CA (1) CA2480125C (da)
DE (1) DE60323351D1 (da)
DK (1) DK1494680T3 (da)
ES (1) ES2312764T3 (da)
HK (1) HK1079996B (da)
IL (1) IL164275A0 (da)
MX (1) MXPA04009288A (da)
NZ (1) NZ535843A (da)
PL (1) PL372346A1 (da)
PT (1) PT1494680E (da)
WO (1) WO2003082300A1 (da)
ZA (1) ZA200408153B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027914A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
NZ545393A (en) * 2003-09-19 2009-10-30 Wisconsin Alumni Res Found 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
CA2563872C (en) * 2004-05-07 2014-11-25 Wisconsin Alumni Research Foundation Method of forming mesenchymal stem cells from embryonic stem cells
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
WO2010120698A1 (en) * 2009-04-17 2010-10-21 Vidasym, Llc Vitamin d receptor agonists and uses thereof
JP6971966B2 (ja) * 2015-08-05 2021-11-24 ウイスコンシン アラムニ リサーチ ファンデーション カルシトリオールの２−メチレン類似体および関連化合物の合成および生物活性
CN111588506B (zh) * 2020-01-02 2022-01-25 南京医科大学 一种含维生素c的钛种植体存储液的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US584928A (en) * 1897-06-22 Schlag
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
IL74617A (en) * 1985-03-15 1988-11-15 Yeda Res & Dev Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5556645A (en) * 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5565589A (en) * 1993-11-03 1996-10-15 Wisconsin Alumni Research Foundation 17-formyl-5,6-trans-vitamin D compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
JP3372259B2 (ja) * 1995-09-21 2003-01-27 ウィスコンシン・アルムニ・リサーチ・ファウンデーション カルシトリオール誘導体およびそれらの用途
US5976142A (en) * 1996-10-16 1999-11-02 Chin; Martin Apparatus and method for distraction osteogenesis of small alveolar bone
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
ES2320603T3 (es) * 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
WO2002005823A2 (en) * 2000-07-14 2002-01-24 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Also Published As

Publication number Publication date
EP1494680B1 (en) 2008-09-03
CA2480125C (en) 2009-12-29
ATE406901T1 (de) 2008-09-15
DK1494680T3 (da) 2008-11-17
US20030195175A1 (en) 2003-10-16
PT1494680E (pt) 2008-10-21
AU2003220169B2 (en) 2008-09-11
CA2480125A1 (en) 2003-10-09
CN100531739C (zh) 2009-08-26
KR20040095346A (ko) 2004-11-12
CN1655797A (zh) 2005-08-17
BR0308701A (pt) 2005-01-18
AU2003220169A1 (en) 2003-10-13
PL372346A1 (en) 2005-07-11
MXPA04009288A (es) 2005-06-08
DE60323351D1 (de) 2008-10-16
KR100983953B1 (ko) 2010-09-27
ES2312764T3 (es) 2009-03-01
ZA200408153B (en) 2006-03-29
NZ535843A (en) 2006-03-31
JP2005527558A (ja) 2005-09-15
US20110112056A1 (en) 2011-05-12
WO2003082300A1 (en) 2003-10-09
HK1079996A1 (zh) 2006-04-21
EP1494680A1 (en) 2005-01-12
US20050203071A1 (en) 2005-09-15
HK1079996B (zh) 2010-04-01

Similar Documents

Publication Publication Date Title
IL164275A0 (en) Pharmaceutical compositions containing carbon-2-modified-viatimin d analogs
Jensen et al. Anterior maxillary alveolar distraction osteogenesis: a prospective 5-year clinical study.
NO20040331L (no) Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
NO20042151L (no) Sammensetning for a forbedre skjelettvekst og opprettholdelse av benhelse
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
IL153908A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2alpha-METHYL-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
ATE365045T1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen,sowie damit verbundene zusammensetzungen und behandlungsformen
MY140080A (en) Treatment and prevention of osteoporosis
EA201001286A1 (ru) Комбинированное применение 25-гидроксивитамина d3 и витамина d3 для повышения плотности минерального вещества костей и для лечения остеопороза
WO2001015715A3 (en) Composition for maintenance of bone or dental health or treatment of bone or dental disorders
El-Ghareeb et al. Nasal floor augmentation for the reconstruction of the atrophic maxilla: a case series
MXPA04004732A (es) Composiciones y estuches que comprenden un compuesto definido de boro, metodos para prepararlas y uso y administracion de las mismas.
Zhao et al. In vitro and in vivo evaluation of the osteogenic ability of implant surfaces with a local delivery of simvastatin.
TW200638946A (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
BG106155A (en) Novel derivatives and analogues of galanthamin
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
Froum et al. Distraction osteogenesis for ridge augmentation: prevention and treatment of complications. thirty case reports.
Kassolis et al. The segmental osteotomy in the management of malposed implants: a case report and literature review
NO20060498L (no) Metode for a promotere benvekst
AU2012377476A8 (en) Preparation and method for the prophylaxis and treatment of atypical osteoporosis
ATE198418T1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
WO2004019873A3 (en) Methods of promoting osteogenesis
ATE413863T1 (de) Sprudelnde pharmazeutische zusammensetzungen mit vitamin d, calcium und phospat und ihre therapeutische verwendung
Anitua et al. Transalveolar nasal floor elevation and implant placement: Long term follow-up case report and description of the technique

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees